Sitting too long may spike blood pressure for 24 hours
NCT ID NCT07396857
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how sitting for 2 hours straight affects blood pressure over the next 24 hours in healthy adults aged 18-65. Researchers will measure artery function and blood pressure before, during, and after sitting, and test if blocking certain artery-relaxing chemicals changes the response. The goal is to understand the hidden effects of prolonged sitting on heart health.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2025
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Are between the ages of 18-65. * Have a body mass index of \<40kg/m2 (non-obese). * Have not smoked nicotine or marijuana-containing products most days of the week within the past 6 months. * Have not been diagnosed with a cardiovascular, cerebrovascular, respiratory, or metabolic disease. * Are normotensive. * Are not currently taking any medications for cardiovascular, metabolic, pulmonary, or neurological disorders, or taking sildenafil regularly. * Are not allergic to the adhesive used to secure the activPAL activity monitors. * Are not pregnant or breastfeeding. * Are not regularly taking any of the following: another anti-fungal, heartburn medications containing cisapride (e.g., Propulsid), depression medications containing amitriptyline (e.g., Elavil) or nortriptyline (e.g., Pamelor), erythromycin (antibiotic), lipid lower medications (i.e., statins), non-steroidal anti-inflammatory drugs (e.g., ibuprofen), or vitamin A supplements. Exclusion Criteria: * o Younger than 18 years old. Individuals younger than 18 demonstrate more variable peak FMD responses and require multiple assessments to determine peak response. * Over the age of 65. There are age-related impacts on arterial function and the responses to sitting. * Body mass index of \>40 kg/m2 (i.e., obese II category)(6-8). * Smoked nicotine or marijuana-containing products most days of the week within the past 6 months. Cardiovascular health for participants who smoke is poor compared to those who do not smoke, which will negatively impact our arterial function outcomes. * Have been diagnosed with a cardiovascular, cerebrovascular, respiratory, or metabolic disease. Such conditions impact our assessments of arterial health. The results of unhealthy participants are not of interest in this study. * Hypertension (seated resting systolic pressure \>139 mmHg and/or diastolic pressure \>89 mmHg). Hypertensive individuals have impairments in artery health, which will affect their baseline artery health measures. * Hypotensive (seated resting systolic pressure \<90 mmHg and/or diastolic pressure \<60 mmHg). Hypotensive people are more likely to experience further reductions in blood pressure during the sitting protocol, which will increase the risk of fainting and/or dizziness. * Have a history of fainting and/or dizziness during sitting or standing. * Prescribed medications for cardiovascular, metabolic, pulmonary, or neurological disorders. This includes people using hormone replacement therapy. These medications will interfere with our assessments and interpretation of arterial health. * Have a known allergy to the clear medical adhesive used to secure the activPAL activity monitors. * Females who are pregnant or breastfeeding. Pregnant and breastfeeding females are ineligible to participate. This is due to the known increases in arterial vasodilation associated with pregnancy related sex hormones. * Currently or recently (within the past 6 months) regularly taking sildenafil or other medications that increase the relaxing effects of nitric oxide in arteries. Such medication will influence artery blood flow and flow-mediated dilation responses. * Are regularly taking any of the following: another anti-fungal, heartburn medications containing cisapride (e.g., Propulsid), depression medications containing amitriptyline (e.g., Elavil) or nortriptyline (e.g., Pamelor), erythromycin (antibiotic), lipid lower medications (i.e., statins), non-steroidal anti-inflammatory drugs (e.g., ibuprofen), or vitamin A supplements. These are to minimize the chance of a participant experiencing an adverse reaction to the fluconazole tablet.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cardiovascular are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Dalhousie University
RECRUITINGHalifax, Nova Scotia, B3H4R2, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Putting Patients' priorities first: a new approach to ease the burden of multiple chronic illnesses
- 4,500 healthy adults tracked to uncover hidden disease risks
- Fitbit for the heart: tiny tracker may speed recovery after surgery
- CRISPR therapy takes aim at stubborn high cholesterol in first human trial
- New blood tests could speed up disease detection
- Million-Person african study aims to fill health data gap